- Datum15.01.2025
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalterstock3
Madrigal Pharmaceuticals Inc. Chart
Du willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnenMadrigal Pharmaceuticals Inc. Realtime-Kurs
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
L&S | VK | |||||
Tradegate | VK | |||||
Stuttgart | VK |
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|
Wertentwicklung (Nasdaq)
Wikifolio
Passender Service zu Madrigal Pharmaceuticals Inc.
Webinar zu Madrigal Pharmaceuticals Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)168,246-368,290
- Jahrestief / Hoch ($)168,246-368,290
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Madrigal Pharmaceuticals Inc.
Termine von Madrigal Pharmaceuticals Inc.
- Feb26Madrigal Pharmaceuticals Inc.Q4 2024 Earnings Release
- Mai13Madrigal Pharmaceuticals Inc.Q1 2025 Earnings Release
- Aug6Madrigal Pharmaceuticals Inc.Q2 2025 Earnings Release
Beschreibung
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.